Relapsed and/or refractory mantle cell lymphoma: What role for temsirolimus?

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 153-164

  Kirschey, Sebastian ^a   Wagner, Susanne ^a   Hess, Georg ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Mantle cell lymphoma; mTOR inhibitor; Temsirolimus

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; BENDAMUSTINE; BLINATUMOMAB; BORTEZOMIB; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; FOSTAMATINIB; GEMCITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INOTUZUMAB OZOGAMICIN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PREDNISONE; RAPAMYCIN; RIFAMPICIN; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; ASTHENIA; CANCER REGRESSION; CANCER RELAPSE; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SCREENING; ENZYME INHIBITION; EPISTAXIS; ERYTHEMA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL IRRITATION; HUMAN; INFECTION; KIDNEY CANCER; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA;

EID: 84859709788     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7327     Document Type: Review

References (63)

1. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. Jan 6, 2011;117(1):26-38.
2. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology/the Education Program of the American Society of Hematology American Society of Hematology. 2009:542-51.
3. Ferrer A, Salaverria I, Bosch F, Villamor N, Rozman M, Bea S, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer. Jun 15, 2007;109(12):2473-80.
4. Cohen PL, Kurtin PJ, Donovan KA, Hanson CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol. May 1998; 101(2):302-10.
5. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. Feb 1, 2003;97(3):586-91.
6. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin- Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. Jan 15, 2008;111(2):558-65.
7. Schmidinger M, Berger W. Temsirolimus. Arzneimittel PROFIL Onkologie. 2007;1-18.
8. Martin P, Coleman M, Leonard JP. Progress in mantle-cell lymphoma. J Clin Oncol. Feb 1, 2009;27(4):481-3.
9. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. Oct 1, 2008;112(7): 2687-93.
10. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and Autologous Stem Cell Transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the european Mantle Cell Lymphoma Network (MCL net). ASH Annual Meeting Abstracts. Nov 19, 2010;116(21):110
11. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Research. Feb 15, 2010;70(4):1408-8.
12. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. Feb 1, 2005;23(4):705-11.
13. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. Mar 20, 2005;23(9):1984-92.
14. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. Dec 15, 2006;108(13):4003-8.
15. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. Oct 1, 2005;23(28):7013-23.
16. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol. Sep 10, 2005;23(26):6409-14.
17. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. August 20, 2009;114(8):1469-76.
18. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma. Dec 2009;50(12):1937-50.
19. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. Apr 1, 2005;105(7):2677-84.
20. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl- Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and lowgrade non-Hodgkin's lymphoma. J Clin Oncol. May 20, 2005;23(15): 3383-9.
21. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. Dec 1, 2003;21(23):4407-12.
22. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. May 2009;145(3):344-9.
23. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. Mar 16, 2010;17(3):249-61.
24. Drakos E, Rassidakis GZ, Medeiros LJ. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med. Feb 4, 2008;10:e4.
25. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene. Feb 16, 2006;25(7):998-1007.
26. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). Mar 1, 2011;3(3):192-222.
27. Samad N, Younes A. Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. Onco Targets Ther. Sep 7, 2010;3:167-78.
28. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. Dec 2009;8(23):3831-7.
29. Galimberti S, Petrini M. Temsirolimus in the treatment of relapsed and/ or refractory mantle cell lymphoma. Cancer Manag Res. Jun 28, 2010;2: 181-9.
30. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. Apr 21, 2006;22(2):159-68.
31. Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev. Mar 2005;69(1):79-100.
32. Lang CH, Frost RA. Endotoxin disrupts the leucine-signaling pathway involving phosphorylation of mTOR, 4E-BP1, and S6K1 in skeletal muscle. Journal of Cellular Physiology. Apr 2005;203(1):144-55.
33. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. Dec 2006;169(6):2171-80.
34. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem. Jun 5, 1998;273(23):14424-9.
35. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. Aug 15, 1995;60(3):264-70.
36. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. Feb 15, 1999;59(4):886-94.
37. Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. Jan 1, 2010;16(1):141-53.
38. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol. Apr 2008;36(4):443-50.
39. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. Jun 15, 2004;22(12):2336-47.
40. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. Mar 1, 2004;22(5):909-18.
41. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. Aug 10, 2005;23(23):5347-56.
42. Ansell SM, Inwards DJ, Rowland KM, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. Aug 1, 2008;113(3):508-14.
43. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. Aug 10, 2009;27(23):3822-9.
44. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. Jan 15, 1994;83(2):435-55.
45. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. Jun 2000;51(6):634-41.
46. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. Mar 1, 1998;91(5):1644-52.
47. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res. Oct 1, 2004;64(19):7117-26.
48. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. Apr 2011;12(4):361-8.
49. El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. Aug 2007;18(8):1363-8.
50. Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. Dec 2008;93(12):1829-36.
51. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndromeassociated Kaposi's sarcoma. Cancer. Dec 15, 2002;95(12):2555-61.
52. Kaufmann H, Raderer M, Wohrer S, Puspok A, Bankier A, Zielinski C, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. Oct 15, 2004;104(8): 2269-71.
53. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. Jul 2011;22(7):1622-7.
54. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. Aug 15, 2008;321(5891):974-7.
55. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. Apr 20, 2010;28(12):2085-93.
56. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. Aug 1, 2009;69(15):6232-40.
57. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J Biol Chem. Mar 20, 2009;284(12): 8023-32.
58. Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, et al. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs. Sep 1, 2011.
59. Cai P, Tsao R, Ruppen ME. In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos. Sep 2007;35(9):1554-63.
60. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther. Jan 2005;77(1):76-89.
61. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. Nov 2007;47(11): 1430-9.
62. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. Mar 2009;20(3):520-5.
63. Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. May 1, 2003;21(9):1740-5.